{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T15:21:39Z","timestamp":1759159299560,"version":"3.37.3"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2024,5,8]],"date-time":"2024-05-08T00:00:00Z","timestamp":1715126400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,5,8]],"date-time":"2024-05-08T00:00:00Z","timestamp":1715126400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Nucl Med"],"published-print":{"date-parts":[[2024,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Objective<\/jats:title>\n                <jats:p><jats:sup>11<\/jats:sup>C-Methionine positron emission tomography (MET-PET) is used for stereotactic radiotherapy planning in meningioma patients. The role of MET-PET during subsequent follow-up (FU) is unclear. We analyzed the uptake of <jats:sup>11<\/jats:sup>C-Methionine before and after stereotactic radiotherapy (SRT) in patients with a complex meningioma and investigated if there was a difference between patients with progressive disease (PD) and stable disease (SD) during FU.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This retrospective study investigates 62 MET-PETs in 29 complex meningioma patients. Standardized uptake value (SUV)<jats:sub>max<\/jats:sub> and SUV<jats:sub>peak<\/jats:sub> tumor-to-normal ratios (T\/N-ratios) were calculated, comparing the tumor region with both the mirroring intracranial area and the right frontal gray matter. The difference in <jats:sup>11<\/jats:sup>C-Methionine uptake pre- and post-SRT was analyzed, as well as the change in uptake between PD or SD.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Median (IQR) FU duration was 67 months (50.5\u201391.0). The uptake of <jats:sup>11<\/jats:sup>C-Methionine in meningiomas remained increased after SRT. Neither a statistically significant difference between MET-PETs before and after SRT was encountered, nor a significant difference in one of the four T\/N-ratios between patients with SD versus PD with median (IQR) SUV<jats:sub>max<\/jats:sub> T\/N<jats:sub>R front<\/jats:sub> 2.65 (2.13\u20133.68) vs 2.97 (1.55\u20133.54) [<jats:italic>p<\/jats:italic>\u2009=\u20090.66]; SUV<jats:sub>max<\/jats:sub> T\/N<jats:sub>mirror<\/jats:sub> 2.92 (2.19\u20133.71) vs 2.95 (1.74\u20133.60) [<jats:italic>p<\/jats:italic>\u2009=\u20090.61]; SUV<jats:sub>peak<\/jats:sub> T\/N<jats:sub>R front<\/jats:sub> 2.35 (1.64\u20133.40) vs 2.25 (1.44\u20133.74) [<jats:italic>p<\/jats:italic>\u2009=\u20090.80]; SUV<jats:sub>peak<\/jats:sub> T\/N<jats:sub>mirror<\/jats:sub> 2.38 (1.91\u20133.36) vs 2.35 (1.56\u20133.72) [<jats:italic>p<\/jats:italic>\u2009=\u20090.95].<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Our data do not support use of MET-PET during FU of complex intracranial meningiomas after SRT. MET-PET could not differentiate between progressive or stable disease.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s12149-024-01932-6","type":"journal-article","created":{"date-parts":[[2024,5,8]],"date-time":"2024-05-08T16:02:26Z","timestamp":1715184146000},"page":"596-606","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["11C-Methionine uptake in meningiomas after stereotactic radiotherapy"],"prefix":"10.1007","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3529-2707","authenticated-orcid":false,"given":"Hanne-Rinck","family":"Jeltema","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bart R. J.","family":"van Dijken","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katalin","family":"Tam\u00e1si","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gea","family":"Drost","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mart A. A. M.","family":"Heesters","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anouk","family":"van der Hoorn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andor W. J. M.","family":"Glaudemans","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. Marc C.","family":"van Dijk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,5,8]]},"reference":[{"key":"1932_CR1","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.clineuro.2009.12.011","volume":"112","author":"GA Alexiou","year":"2010","unstructured":"Alexiou GA, Gogou P, Markoula S, Kyritsis AP. Management of meningiomas. Clin Neurol Neurosurg. 2010;112:177\u201382.","journal-title":"Clin Neurol Neurosurg"},{"issue":"4","key":"1932_CR2","doi-asserted-by":"crossref","first-page":"104","DOI":"10.3390\/bioengineering5040104","volume":"5","author":"AM Najjar","year":"2018","unstructured":"Najjar AM, Johnson JM, Schellingerhout D. The emerging role of amino acid PET in neuro-oncology. Bioengineering. 2018;5(4):104.","journal-title":"Bioengineering"},{"key":"1932_CR3","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/s00259-012-2295-5","volume":"40","author":"AWJM Glaudemans","year":"2013","unstructured":"Glaudemans AWJM, Enting RH, Heesters MAAM, Dierckx RAJO, Van Rheenen RWJ, Walenkamp AME, et al. Value of 11C-Methionine PET in imaging brain tumours and metastases. Eur J Nucl Med Mol Imaging. 2013;40:615\u201335.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"1932_CR4","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1097\/RLU.0b013e318238f51a","volume":"37","author":"M Tripathi","year":"2012","unstructured":"Tripathi M, Sharma R, Varshney R, Jaimini A, Jain J, Souza MMD, et al. Comparison of F-18 FDG and C-11 Methionine PET\/CT for the evaluation of recurrent primary brain tumors. Clin Nucl Med. 2012;37(2):158\u201363.","journal-title":"Clin Nucl Med"},{"issue":"7","key":"1932_CR5","doi-asserted-by":"crossref","first-page":"918","DOI":"10.2967\/jnumed.120.254243","volume":"62","author":"G Ceccon","year":"2021","unstructured":"Ceccon G, Lohmann P, Werner JM, Tscherpel C, Dunkl V, Stoffels G, et al. Early treatment response assessment using 18F-FET PET compared with contrast-enhanced MRI in glioma patients after adjuvant temozolomide chemotherapy. J Nucl Med. 2021;62(7):918\u201325.","journal-title":"J Nucl Med"},{"key":"1932_CR6","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.ymeth.2017.05.019","volume":"130","author":"KJ Langen","year":"2017","unstructured":"Langen KJ, Stoffels G, Filss C, Heinzel A, Stegmayr C, Lohmann P, et al. Imaging of amino acid transport in brain tumours: positron emission tomography with O-(2-[18F]fluoroethyl)-l-tyrosine (FET). Methods. 2017;130:124\u201334.","journal-title":"Methods"},{"key":"1932_CR7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/1536012116687651","volume":"16","author":"KR Laukamp","year":"2017","unstructured":"Laukamp KR, Lindemann F, Weckesser M, Hesselmann V, Ligges S, W\u00f6lfer J, et al. Multimodal imaging of patients with gliomas confirms 11C-MET PET as a complementary marker to MRI for noninvasive tumor grading and intraindividual follow-up after therapy. Mol Imaging. 2017;16:1\u201312.","journal-title":"Mol Imaging."},{"issue":"2","key":"1932_CR8","doi-asserted-by":"crossref","first-page":"229","DOI":"10.2967\/jnumed.112.109603","volume":"54","author":"M Rapp","year":"2013","unstructured":"Rapp M, Heinzel A, Galldiks N, Stoffels G, Felsberg J, Ewelt C, et al. Diagnostic performance of 18F-FET PET in newly diagnosed cerebral lesions suggestive of glioma. J Nucl Med. 2013;54(2):229\u201335.","journal-title":"J Nucl Med"},{"issue":"3","key":"1932_CR9","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/s00259-014-2934-0","volume":"42","author":"JF Cornelius","year":"2015","unstructured":"Cornelius JF, Stoffels G, Fil\u00df C, Galldiks N, Slotty P, Kamp M, et al. Uptake and tracer kinetics of O-(2\u201318F-fluoroethyl)-l-tyrosine in meningiomas: preliminary results. Eur J Nucl Med Mol Imaging. 2015;42(3):459\u201367.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"1932_CR10","doi-asserted-by":"crossref","first-page":"e22","DOI":"10.1097\/RLU.0000000000002350","volume":"44","author":"V Basse","year":"2019","unstructured":"Basse V, Dissaux G, Seizeur R, Bourhis D, Querellou S. Uptake and tracer kinetic of O-(2-(18)F-fluoroethyl)-l-tyrosine in meningioma. Clin Nucl Med. 2019;44(1):e22\u20133.","journal-title":"Clin Nucl Med"},{"issue":"1","key":"1932_CR11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12885-017-3702-x","volume":"17","author":"S Yomo","year":"2017","unstructured":"Yomo S, Oguchi K. Prospective study of 11C-Methionine PET for distinguishing between recurrent brain metastases and radiation necrosis: limitations of diagnostic accuracy and long-term results of salvage treatment. BMC Cancer. 2017;17(1):1.","journal-title":"BMC Cancer"},{"issue":"8","key":"1932_CR12","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.3174\/ajnr.A5252","volume":"38","author":"N Tomura","year":"2017","unstructured":"Tomura N, Kokubun M, Saginoya T, Mizuno Y, Kikuchi Y. Differentiation between treatment-induced necrosis and recurrent tumors in patients with metastatic brain tumors: comparison among 11C-Methionine-PET, FDG-PET, MR permeability imaging, and MRI-ADC-preliminary results. Am J Neuroradiol. 2017;38(8):1520\u20137.","journal-title":"Am J Neuroradiol"},{"issue":"2","key":"1932_CR13","first-page":"281","volume":"19","author":"G Ceccon","year":"2017","unstructured":"Ceccon G, Lohmann P, Stoffels G, Judov N, Filss CP, Rapp M, et al. Dynamic O-(2\u201318F-fluoroethyl)-l-tyrosine positron emission tomography differentiates brain metastasis recurrence from radiation injury after radiotherapy. Neuro Oncol. 2017;19(2):281\u20138.","journal-title":"Neuro Oncol"},{"issue":"1","key":"1932_CR14","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S0360-3016(00)00604-0","volume":"48","author":"J Nuutinen","year":"2000","unstructured":"Nuutinen J, Sonninen P, Lehikoinen P, Sutinen E, Valavaara R, Eronen E, et al. Radiotherapy treatment planning and long-term follow-up with [11 C]Methionine PET in patients with low-grade astrocytoma. Int J Radiot Oncol Biol Phys. 2000;48(1):43\u201352.","journal-title":"Int J Radiot Oncol Biol Phys"},{"issue":"19","key":"1932_CR15","doi-asserted-by":"crossref","first-page":"47777","DOI":"10.3390\/cancers13194777","volume":"13","author":"MV Mattoli","year":"2021","unstructured":"Mattoli MV, Trevisi G, Scolozzi V, Capotosti A, Cocciolillo F, Marini I, et al. Dynamic 11C-Methionine PET-CT: prognostic factors for disease progression and survival in patients with suspected glioma recurrence. Cancers. 2021;13(19):47777.","journal-title":"Cancers"},{"issue":"4","key":"1932_CR16","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1016\/j.ijrobp.2008.02.058","volume":"72","author":"ST Astner","year":"2008","unstructured":"Astner ST, Dobrei-Ciuchendea M, Essler M, Bundschuh RA, Sai H, Schwaiger M, et al. Effect of 11C-Methionine-positron emission tomography on gross tumor volume delineation in stereotactic radiotherapy of skull base meningiomas. Int J Radiat Oncol Biol Phys. 2008;72(4):1161\u20137.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"6","key":"1932_CR17","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1007\/s00259-019-04591-2","volume":"47","author":"KA Kessel","year":"2020","unstructured":"Kessel KA, Weber W, Yakushev I, Fischer H, Voglhuber T, Diehl C, et al. Integration of PET-imaging into radiotherapy treatment planning for low-grade meningiomas improves outcome. Eur J Nucl Med Mol Imaging. 2020;47(6):1391\u20139.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"1932_CR18","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.ijrobp.2006.02.047","volume":"66","author":"AL Grosu","year":"2006","unstructured":"Grosu AL, Weber WA, Astner ST, Adam M, Krause BJ, Schwaiger M, et al. 11C-Methionine PET improves the target volume delineation of meningiomas treated with stereotactic fractionated radiotherapy. Int J Radiat Oncol Biol Phys. 2006;66(2):339\u201344.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"1932_CR19","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1007\/s12149-017-1227-7","volume":"32","author":"A Kits","year":"2018","unstructured":"Kits A, Martin H, Sanchez-Crespo A, Delgado AF. Diagnostic accuracy of 11C-Methionine PET in detecting neuropathologically confirmed recurrent brain tumor after radiation therapy. Ann Nucl Med. 2018;32(2):132\u201341.","journal-title":"Ann Nucl Med"},{"key":"1932_CR20","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.ejrad.2018.04.003","volume":"103","author":"T Pyka","year":"2018","unstructured":"Pyka T, Hiob D, Preibisch C, Gempt J, Wiestler B, Schlegel J, et al. Diagnosis of glioma recurrence using multiparametric dynamic 18F-fluoroethyl-tyrosine PET-MRI. Eur J Radiol. 2018;103:32\u20137.","journal-title":"Eur J Radiol"},{"issue":"53","key":"1932_CR21","doi-asserted-by":"crossref","first-page":"91030","DOI":"10.18632\/oncotarget.19024","volume":"8","author":"W Xu","year":"2017","unstructured":"Xu W, Gao L, Shao A, Zheng J, Zhang J. The performance of 11C-Methionine PET in the differential diagnosis of glioma recurrence. Oncotarget. 2017;8(53):91030\u20139.","journal-title":"Oncotarget"},{"issue":"9","key":"1932_CR22","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.3390\/cancers13092093","volume":"13","author":"A Holzgreve","year":"2021","unstructured":"Holzgreve A, Albert NL, Galldiks N, Suchorska B. Use of pet imaging in neuro-oncological surgery. Cancers. 2021;13(9):2093.","journal-title":"Cancers"},{"issue":"5","key":"1932_CR23","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.3390\/cancers14051103","volume":"14","author":"A Verger","year":"2022","unstructured":"Verger A, Kas A, Darcourt J, Guedj E. PET imaging in neuro-oncology: an update and overview of a rapidly growing area. Cancers. 2022;14(5):1103.","journal-title":"Cancers"},{"issue":"12","key":"1932_CR24","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1093\/neuonc\/nox112","volume":"19","author":"N Galldiks","year":"2017","unstructured":"Galldiks N, Albert NL, Sommerauer M, Grosu AL, Ganswindt U, Law I, et al. PET imaging in patients with meningioma\u2014report of the RANO\/PET group. Neuro Oncol. 2017;19(12):1576\u201387.","journal-title":"Neuro Oncol"},{"key":"1932_CR25","first-page":"I84","volume":"5","author":"N Galldiks","year":"2023","unstructured":"Galldiks N, Albert NL, Wollring M, Werner JM, Lohmann P, Villanueva-Meyer JE, et al. Advances in PET imaging for meningioma patients. Neurooncol Adv. 2023;5:I84-93.","journal-title":"Neurooncol Adv"},{"key":"1932_CR26","doi-asserted-by":"crossref","first-page":"120","DOI":"10.3389\/fneur.2016.00120","volume":"7","author":"N Galldiks","year":"2016","unstructured":"Galldiks N, Langen KJ. Amino acid PET\u2014an imaging option to identify treatment response, posttherapeutic effects, and tumor recurrence? Front Neurol. 2016;7:120.","journal-title":"Front Neurol"},{"issue":"4","key":"1932_CR27","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1007\/s11307-018-1163-5","volume":"20","author":"A Peko\u0161ak","year":"2018","unstructured":"Peko\u0161ak A, Filp U, Poot AJ, Windhorst AD. From carbon-11-labeled amino acids to peptides in positron emission tomography: the synthesis and clinical application. Mol Imaging Biol. 2018;20(4):510\u201332.","journal-title":"Mol Imaging Biol"},{"issue":"8","key":"1932_CR28","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1007\/s00259-016-3310-z","volume":"43","author":"M Ryttlefors","year":"2016","unstructured":"Ryttlefors M, Danfors T, Latini F, Montelius A, Blomquist E, Gudjonsson O. Long-term evaluation of the effect of hypofractionated high-energy proton treatment of benign meningiomas by means of 11C-l-Methionine positron emission tomography. Eur J Nucl Med Mol Imaging. 2016;43(8):1432\u201343.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"8","key":"1932_CR29","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1007\/s12149-013-0747-z","volume":"27","author":"H Ikeda","year":"2013","unstructured":"Ikeda H, Tsuyuguchi N, Kunihiro N, Ishibashi K, Goto T, Ohata K. Analysis of progression and recurrence of meningioma using 11C-Methionine PET. Ann Nucl Med. 2013;27(8):772\u201380.","journal-title":"Ann Nucl Med"},{"issue":"12","key":"1932_CR30","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1007\/s002590000335","volume":"27","author":"O Gudjonsson","year":"2000","unstructured":"Gudjonsson O, Blomquist E, Lilja A, Ericson H, Bergstr\u00f6m M, Nyberg G. Evaluation of the effect of high-energy proton irradiation treatment on meningiomas by means of 11C-l-Methionine PET. Eur J Nucl Med. 2000;27(12):1793\u20139.","journal-title":"Eur J Nucl Med"},{"issue":"11","key":"1932_CR31","first-page":"1792","volume":"63","author":"H-R Jeltema","year":"2021","unstructured":"Jeltema H-R, Jansen MR, Potgieser ARE, van Asselt ADI, Heesters MAAM, van de Hoorn A, et al. Study on intracranial meningioma using PET ligand investigation during follow-up over years (SIMPLIFY). Neuroradiology. 2021;63(11):1792\u20139.","journal-title":"Neuroradiology"},{"issue":"11","key":"1932_CR32","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1007\/s00259-006-0206-3","volume":"33","author":"T Vander Borght","year":"2006","unstructured":"Vander Borght T, Asenbaum S, Bartenstein P, Halldin C, Kapucu \u00d6, Van Laere K, et al. EANM procedure guidelines for brain tumour imaging using labelled amino acid analogues. Eur J Nucl Med Mol Imaging. 2006;33(11):1374\u201380.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"1932_CR33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/ijms23031919","volume":"23","author":"N Korimerla","year":"2022","unstructured":"Korimerla N, Wahl DR. Interactions between radiation and one-carbon metabolism. Int J Mol Sci. 2022;23(3):1\u201314.","journal-title":"Int J Mol Sci"},{"issue":"4","key":"1932_CR34","doi-asserted-by":"crossref","first-page":"127","DOI":"10.3390\/diagnostics9040127","volume":"9","author":"V Cuccurullo","year":"2019","unstructured":"Cuccurullo V, Di Stasio GD, Cascini GL, Gatta G, Bianco C. The molecular effects of ionizing radiations on brain cells: radiation necrosis vs. tumor recurrence. Diagnostics. 2019;9(4):127.","journal-title":"Diagnostics"},{"issue":"3","key":"1932_CR35","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1007\/s11060-018-2919-0","volume":"139","author":"B Suchorska","year":"2018","unstructured":"Suchorska B, Unterrainer M, Biczok A, Sosnova M, Forbrig R, Bartenstein P, et al. 18F-FET-PET as a biomarker for therapy response in non-contrast enhancing glioma following chemotherapy. J Neurooncol. 2018;139(3):721\u201330.","journal-title":"J Neurooncol"},{"issue":"14","key":"1932_CR36","doi-asserted-by":"crossref","first-page":"3336","DOI":"10.3390\/cancers14143336","volume":"14","author":"A Heinzel","year":"2022","unstructured":"Heinzel A, Dedic D, Galldiks N, Lohmann P, Stoffels G, Filss CP, et al. Two decades of brain tumour imaging with O-(2-[18F]fluoroethyl)-l-tyrosine PET: the Forschungszentrum J\u00fclich experience. Cancers. 2022;14(14):3336.","journal-title":"Cancers"},{"issue":"2","key":"1932_CR37","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1093\/neuonc\/nou131","volume":"17","author":"A Afshar-Oromieh","year":"2015","unstructured":"Afshar-Oromieh A, Wolf MB, Kratochwil C, Giesel FL, Combs SE, Dimitrakopoulou-Strauss A, et al. Comparison of 68 Ga-DOTATOC-PET\/CT and PET\/MRI hybrid systems in patients with cranial meningioma: Initial results. Neuro Oncol. 2015;17(2):312\u20139.","journal-title":"Neuro Oncol"},{"issue":"3","key":"1932_CR38","doi-asserted-by":"crossref","first-page":"347","DOI":"10.2967\/jnumed.114.149120","volume":"56","author":"W Rachinger","year":"2015","unstructured":"Rachinger W, Stoecklein VM, Terpolilli NA, Haug AR, Ertl L, P\u00f6schl J, et al. Increased 68Ga-DOTATATE uptake in PET imaging discriminates meningioma and tumor-free tissue. J Nucl Med. 2015;56(3):347\u201353.","journal-title":"J Nucl Med"},{"issue":"1","key":"1932_CR39","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1186\/s13014-021-01875-6","volume":"16","author":"ES Kowalski","year":"2021","unstructured":"Kowalski ES, Khairnar R, Gryaznov AA, Kesari V, Koroulakis A, Raghavan P, et al. 68Ga-DOTATATE PET-CT as a tool for radiation planning and evaluating treatment responses in the clinical management of meningiomas. Radiat Oncol. 2021;16(1):151.","journal-title":"Radiat Oncol"},{"issue":"5","key":"1932_CR40","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1111\/jon.12632","volume":"29","author":"J Ivanidze","year":"2019","unstructured":"Ivanidze J, Roytman M, Lin E, Magge RS, Pisapia DJ, Liechty B, et al. Gallium-68 DOTATATE PET in the evaluation of intracranial meningiomas. J Neuroimaging. 2019;29(5):650\u20136.","journal-title":"J Neuroimaging"},{"issue":"9","key":"1932_CR41","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1007\/s00259-012-2155-3","volume":"39","author":"A Afshar-Oromieh","year":"2012","unstructured":"Afshar-Oromieh A, Giesel FL, Linhart HG, Haberkorn U, Haufe S, Combs SE, et al. Detection of cranial meningiomas: comparison of 68Ga-DOTATOC PET\/CT and contrast-enhanced MRI. Eur J Nucl Med Mol Imaging. 2012;39(9):1409\u201315.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"4","key":"1932_CR42","doi-asserted-by":"crossref","first-page":"278","DOI":"10.4103\/ijnm.IJNM_98_19","volume":"34","author":"M Pelak","year":"2019","unstructured":"Pelak M, D\u2019Amico A. The Prognostic value of pretreatment gallium-68 DOTATATE positron emission tomography\/computed tomography in irradiated non-benign meningioma. Indian J Nucl Med. 2019;34(4):278\u201383.","journal-title":"Indian J Nucl Med"},{"issue":"1","key":"1932_CR43","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s13014-018-1008-z","volume":"13","author":"F Stade","year":"2018","unstructured":"Stade F, Dittmar JO, J\u00e4kel O, Kratochwil C, Haberkorn U, Debus J, et al. Influence of 68Ga-DOTATOC on sparing of normal tissue for radiation therapy of skull base meningioma: differential impact of photon and proton radiotherapy. Radiat Oncol. 2018;13(1):58.","journal-title":"Radiat Oncol"},{"issue":"1","key":"1932_CR44","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.ijrobp.2005.12.006","volume":"65","author":"S Milker-Zabel","year":"2006","unstructured":"Milker-Zabel S, Zabel-du Bois A, Henze M, Huber P, Schulz-Ertner D, Hoess A, et al. Improved target volume definition for fractionated stereotactic radiotherapy in patients with intracranial meningiomas by correlation of CT, MRI, and [68Ga]-DOTATOC-PET. Int J Radiat Oncol Biol Phys. 2006;65(1):222\u20137.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"1932_CR45","first-page":"vdab012","volume":"3","author":"SS Mahase","year":"2021","unstructured":"Mahase SS, Roth O\u2019Brien DA, No D, Roytman M, Skafida ME, Lin E, et al. [68Ga]-DOTATATE PET\/MRI as an adjunct imaging modality for radiation treatment planning of meningiomas. Neurooncol Adv. 2021;3(1):vdab012.","journal-title":"Neurooncol Adv"},{"issue":"1","key":"1932_CR46","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1186\/s13014-017-0913-x","volume":"12","author":"JO Dittmar","year":"2017","unstructured":"Dittmar JO, Kratochwil C, Dittmar A, Welzel T, Habermehl D, Rieken S, et al. First intraindividual comparison of contrast-enhanced MRI, FET- and DOTATOC- PET in patients with intracranial meningiomas. Radiat Oncol. 2017;12(1):169.","journal-title":"Radiat Oncol"},{"issue":"7","key":"1932_CR47","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1093\/neuonc\/now001","volume":"18","author":"M Sommerauer","year":"2016","unstructured":"Sommerauer M, Burkhardt JK, Frontzek K, Rushing E, Buck A, Krayenbuehl N, et al. 68Gallium-DOTATATE PET in meningioma: a reliable predictor of tumor growth rate? Neuro Oncol. 2016;18(7):1021\u20137.","journal-title":"Neuro Oncol"},{"issue":"3","key":"1932_CR48","doi-asserted-by":"crossref","first-page":"375","DOI":"10.3390\/brainsci11030375","volume":"11","author":"F Barone","year":"2021","unstructured":"Barone F, Inserra F, Scalia G, Ippolito M, Cosentino S, Crea A, et al. 68Gga-dotatoc pet\/ct follow up after single or hypofractionated gamma knife icon radiosurgery for meningioma patients. Brain Sci. 2021;11(3):375.","journal-title":"Brain Sci"},{"issue":"4","key":"1932_CR49","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1007\/s00066-022-02010-4","volume":"199","author":"C L\u00fctgendorf-Caucig","year":"2022","unstructured":"L\u00fctgendorf-Caucig C, Pelak M, Flechl B, Georg P, Fossati P, Stock M, et al. The trends and significance of SSTR PET\/CT added to MRI in follow-up imaging of low-grade meningioma treated with fractionated proton therapy. Strahlenther Onkol. 2022;199(4):396\u2013403.","journal-title":"Strahlenther Onkol"}],"container-title":["Annals of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12149-024-01932-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12149-024-01932-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12149-024-01932-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,26]],"date-time":"2024-07-26T21:19:05Z","timestamp":1722028745000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12149-024-01932-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,8]]},"references-count":49,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["1932"],"URL":"https:\/\/doi.org\/10.1007\/s12149-024-01932-6","relation":{},"ISSN":["0914-7187","1864-6433"],"issn-type":[{"type":"print","value":"0914-7187"},{"type":"electronic","value":"1864-6433"}],"subject":[],"published":{"date-parts":[[2024,5,8]]},"assertion":[{"value":"6 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}